君实生物：偌考奇拜单抗注射液新药上市申请获得受理

Group 1 - The core point of the article is that Junshi Biosciences has received acceptance for its new drug application for JS005, a monoclonal antibody targeting IL-17A, for the treatment of moderate to severe plaque psoriasis in adults [1] - JS005 is a recombinant humanized monoclonal antibody that specifically targets IL-17A, which is associated with autoimmune diseases such as psoriasis, rheumatoid arthritis, and ankylosing spondylitis [1] - The drug works by binding with high affinity to IL-17A and selectively blocking its interaction with receptors IL-17RA/IL-17RC, thereby inhibiting downstream signaling pathways and the release of inflammatory factors [1] Group 2 - Psoriasis is a common chronic, relapsing, inflammatory, and systemic immune-mediated disease, with a prevalence rate in China reaching 0.47% in 2008, significantly higher than 0.12% in 1984 [2] - Moderate to severe psoriasis patients have an increased risk of metabolic syndrome and atherosclerotic cardiovascular diseases, as well as mental health issues such as depression, anxiety, and suicidal tendencies [2] - Psoriasis severely impacts the physical and mental health of patients, highlighting the need for effective treatment options [2]